8. Argenx SE (NASDAQ:ARGX)
Argenx SE continues to build momentum through strong demand for its flagship drug Vyvgart. On April 14, TD Cowen maintained a Buy rating and $1,146 price target, citing survey data from neurologists indicating that first-quarter sales could exceed consensus estimates.
The firm’s quarterly survey of 30 neurologists treating generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy confirmed sustained demand and growing preference for the Vyvgart Hytrulo prefilled syringe.
Revenue expectations are anchored around $1.27 billion for the quarter, with upside driven by adoption of the more convenient delivery format. The prefilled syringe continues to gain traction across multiple indications.
Additional catalysts include upcoming regulatory decisions. A submission for ocular myasthenia gravis is expected soon, while a regulatory decision for seronegative myasthenia gravis is scheduled for May 10.
The expansion across indications and improved delivery formats continues to drive both volume growth and market penetration.
Click next to see the following stock...
